Beam Therapeutics (BEAM) Net Margin (2019 - 2026)
Beam Therapeutics' (BEAM) quarterly Net Margin came in at 297.18% in Q1 2026, up 115302.0% year-on-year from N/an in Q1 2025, and down 238.81% on a QoQ basis from 214.09% in Q4 2025.
Beam Therapeutics (BEAM) Net Margin (2019 - 2026) Analysis & Trends
Beam Therapeutics (BEAM) has 8 years of Net Margin data on file, last reported at 297.18% in Q1 2026.
- On a quarterly basis, Net Margin rose 115302.0% year-over-year to 297.18% in Q1 2026; TTM through Mar 2026 was 39.66%, a 56811.0% increase from a year earlier, with the FY2025 full-year figure at 57.24%, up 53588.0% from the prior year.
- Net Margin for Q1 2026 stood at 297.18%, down from 214.09% in the prior quarter.
- Over the last five years, Net Margin for BEAM reached as high as 214.09% in Q4 2025 and fell as low as 1450.2% in Q1 2025.
- Historically, Net Margin has averaged 614.62% across 5 years, with a median of 558.88% in 2023.
- Across the five-year window, Net Margin soared 335851248 bps in 2022 and slumped 93310 bps in 2024, its largest moves.
- Year by year, Net Margin stood at 191.39% in 2022, then soared by 124 bps to 45.16% in 2023, then slumped by 765 bps to 300.51% in 2024, then jumped by 171 bps to 214.09% in 2025, then plunged by 239 bps to 297.18% in 2026.
- Per Business Quant data, the three most recent Net Margin figures were 297.18% in Q1 2026, 214.09% in Q4 2025, and 1162.38% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 15.02% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 30.33% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Beam Therapeutics | 2.68 Bn | 2.68 Bn | - | -297.18% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -297.18% |
| Dec 31, 2025 | 214.09% |
| Sep 30, 2025 | -1,162.38% |
| Jun 30, 2025 | -1,208.26% |
| Mar 31, 2025 | -1,450.20% |
| Dec 31, 2024 | -300.51% |
| Sep 30, 2024 | -677.47% |
| Jun 30, 2024 | -773.45% |
| Mar 31, 2024 | -1,331.57% |
| Dec 31, 2023 | 45.16% |
| Sep 30, 2023 | -558.88% |
| Jun 30, 2023 | -411.49% |
| Mar 31, 2023 | -398.46% |
| Dec 31, 2022 | -191.39% |
| Sep 30, 2022 | -693.56% |
| Jun 30, 2022 | -432.08% |
| Mar 31, 2022 | -820.85% |
| Dec 31, 2021 | -126.71% |
| Sep 30, 2021 | -3,685.19% |
| Jun 30, 2021 | -1,270,883.33% |